The strong revenue growth and strengthened balance sheet are bullish, but the GAAP EPS beat is non-recurring. Monitor for sustainability of MIPLYFFA revenue and EU approval progress. The debt-free position reduces risk, but future quarters will need to show organic earnings power.
Price Chart
Executive Summary
Zevra Therapeutics reported Q1 2026 net revenue of $36.2M (up 78% YoY) and GAAP diluted EPS of $0.60, massively beating the $0.06 consensus. Results were boosted by a $50M SDX portfolio sale and debt repayment, leaving a debt-free balance sheet with $237M cash. Underlying revenue growth from MIPLYFFA is strong, but the EPS beat is largely one-time.
Key Financial Metrics
Key Facts
- Q1 2026 net revenue $36.2M, +78% YoY vs $20.4M
- GAAP diluted EPS $0.60 vs consensus $0.06 (900% beat)
- Completed $50M SDX portfolio sale to Commave Therapeutics
- Prepaid $63.1M term loan, now debt-free
- Cash, cash equivalents and securities $236.8M as of March 31, 2026
- MIPLYFFA prescription enrollment forms total 170 since launch
Financial Impact
GAAP net income $37.9M vs loss of $3.1M in Q1 2025; adjusted net income $11.5M or $0.18 per share
Risk Factors
- One-time gains from asset sale and debt extinguishment inflated GAAP EPS
- MIPLYFFA revenue concentration
- EU approval for arimoclomol still pending
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001434647-26-000029 |
| Document: zvra-20260506.htm | 0001434647-26-000029 |
| Document: 0001434647-26-000029-index-headers.html | 0001434647-26-000029 |
| Document: 0001434647-26-000029-index.html | 0001434647-26-000029 |
| Document: 0001434647-26-000029.txt | 0001434647-26-000029 |
| 8-K Data (Synthetic) | 0001434647-26-000029 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | Insider Cluster | $11.57 | awaiting T+60 | — | $10.06 (−13.09%) |
May 6, 2026 24w ago | 8-K | $11.00 $10.06 | ▼ −8.59% | ▼ −12.42% | $10.06 (−8.59%) |
Apr 22, 2026 26w ago | Press Release | $10.49 $12.77 | ▲ +21.73% | ▲ +16.96% | $10.06 (−4.15%) |
Mar 2, 2026 34w ago | Press Release | $9.09 $10.32 | ▲ +13.53% | ▲ +4.20% | $10.06 (+10.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers